Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Strip Clear all
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

NCT02651467
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0), Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5), Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 4, 2026, 11:36 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

NCT05586542
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
DERMASEAL, Plasma Film, Standard of Care
Combination Product · Biological · Other
Lead sponsor
Vitruvian Medical Devices, Inc.
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Fresno, California • South Miami, Florida • Boardman, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)

NCT03549117
View directory record Official record
Conditions
Congestion, Nasal
Interventions
Breathe Right Tan (small/medium) nasal strips, Placebo nasal strip
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Verona, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Not applicable Interventional Results available

Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity

NCT02113579
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Mouth Rinse 12027-033, Placebo Mouth Rinse
Device · Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects

NCT03196219
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2, Placebo
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kalispell, Montana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

5% Topical Ibuprofen (IBU) for Ankle Sprain

NCT01945034
View directory record Official record
Conditions
Ankle Injuries
Interventions
Topical IBU twice daily, Placebo twice daily, Topical IBU three times daily, Placebo three times daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Sheffield, Alabama • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

NCT02586493
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Jasper, Alabama • Clearwater, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061
View directory record Official record
Conditions
Asthma
Interventions
Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 4, 2026, 11:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Lesion Progression After Icon Treatment in Young Adults

NCT01988337
View directory record Official record
Conditions
Caries, Salivary Function, Tooth Sensitivity
Interventions
Resin infiltration, Mock treatment
Device · Other
Lead sponsor
DMG Dental Material Gesellschaft mbH
Industry
Eligibility
19 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sunscreen Based on Bioadhesive Nanoparticles

NCT02668536
View directory record Official record
Conditions
Melanoma, UV Ray Skin Damage
Interventions
Standard Sunscreen, BNP
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips

NCT05574049
View directory record Official record
Conditions
Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia
Interventions
Tetrahydrocannabivarin, Placebo
Drug · Other
Lead sponsor
Medical Life Care Planners, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 4, 2026, 11:36 PM EDT
Terminated Not applicable Interventional Results available

Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

NCT02161484
View directory record Official record
Conditions
Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
Interventions
Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%
Procedure · Drug
Lead sponsor
Rita Merman
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Subjective Sleep Study of a Prototype Nasal Dilator

NCT01122849
View directory record Official record
Conditions
Sleep Disorders, Congestion, Nasal
Interventions
Prototype Nasal Dilator, Marketed Nasal Strip, Placebo Nasal Strip
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Paramus, New Jersey • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity

NCT02476032
View directory record Official record
Conditions
Tooth Sensitivity
Interventions
Prof applied oxalate, Self applied oxalate, Prof applied placebo
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application

NCT03052842
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Strip, Placebo Strip
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Kalispell, Montana • Bedford, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 4, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

NCT02586506
View directory record Official record
Conditions
Asthma
Interventions
Placebo ELLIPTA inhaler, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 4, 2026, 11:36 PM EDT
Terminated Phase 3 Interventional Results available

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506
View directory record Official record
Conditions
Contraception
Interventions
NOMAC-E2 COC
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
14 Years to 35 Years · Female only
Enrollment
3,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 4, 2026, 11:36 PM EDT